In a recurring feature, PharmAsia News combs through quarterly earnings reports to bring you highlights on emerging markets. For the previous story, see: ([A#28140503002]).
Emerging Markets Earnings Roundup: Pfizer (Part 11)
Pfizer emerging markets growth lagged in the first quarter, something executives said would turnaround for the rest of the year. But it was almost more interesting for what they didn’t say about how AstraZeneca would fit into the emerging markets picture – particularly because the British firm had solid first quarter results in those markets, especially China.